HEALTH PROFESSIONAL · SOURCE READING

Preoperative therapy for HER2-positive breast cancer

Source: Breast Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: April 25, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Systemic Therapy for Stages I, II, and III Breast Cancer / Stages I, II, and III HER2-Positive Breast Cancer

After the success in the adjuvant setting, initial reports from phase II studies indicated improved pCR rates when trastuzumab, a monoclonal antibody that binds the extracellular domain of HER2, was added to preoperative anthracycline/taxane–based regimens.[112][Level of evidence B3] This has been confirmed in phase III studies.[113,114]

Source links and citations

Continue within this section

Trastuzumab →Pertuzumab →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice